{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"JNJ-26481585"},{"type":"Synonym","name":"HDAC inhibitor JNJ-26481585"}],"definition":{"html":"An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Quisinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of  tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation.","text":"An orally bioavailable, second-generation, hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. Quisinostat inhibits HDAC leading to an accumulation of highly acetylated histones, which may result in an induction of chromatin remodeling; inhibition of the transcription of tumor suppressor genes; inhibition of  tumor cell division; and the induction of tumor cell apoptosis. HDAC, an enzyme upregulated in many tumor types, deacetylates chromatin histone proteins. Compared to some first generation HDAC inhibitors, JNJ-26481585 may induce superior HSP70 upregulation and bcl-2 downregulation."},"drugInfoSummaryLink":null,"nciConceptId":"C77912","nciConceptName":"Quisinostat","termId":596704,"name":"quisinostat","firstLetter":"q","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"quisinostat"}],"links":null}